These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...
The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...
A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...
The FDA has approved Vertex Pharmaceuticals’ Journavx, a new pain medication designed to reduce the risk of addiction and overdose associated with opioids. Intended for short-term pain after surgeries ...
On Thursday, the Food and Drug Administration approved the non-opioid pain relievers from Vertex Pharmaceuticals, a new ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...